• Poster

Cost-effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis in the Presence of Long-Term Clinical Evidence

Citation

Graham, J. B., Earnshaw, S. R., Castelli-Haley, J., Oleen-Burkey, M., & Johnson, K. P. (2007, October). Cost-effectiveness of Glatiramer Acetate and Natalizumab in Relapsing-Remitting Multiple Sclerosis in the Presence of Long-Term Clinical Evidence. Presented at ISPOR 10th Annual European Congress, .

Abstract